Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
OBJECTIVE
To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates.


METHODS
The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium.


RESULTS
Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required > or =16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species.


CONCLUSIONS
Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.
Piddock
Laura J V
LJ
Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, UK. l.j.v.piddock@bham.ac.uk
Johnson
M M
MM
Webber
Mark A
MA
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000235:genetics; D001424:Bacterial Infections / Q000382:microbiology; D002939:Ciprofloxacin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D007769:Lactams / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics; D009268:Nalidixic Acid / Q000494:pharmacology; D010641:Phenotype; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013845:Thienamycins / Q000494:pharmacology*; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D007769:Lactams; D013845:Thienamycins; D047090:beta-Lactams; D009268:Nalidixic Acid; D002939:Ciprofloxacin; D015378:Imipenem; C107057:fropenem